II. Preparations

  1. Tenofovir Disoproxil Fumarate (TDF)
    1. Original Tenofovir formulation and used in Stribild, Truvada and Complera
    2. Associated with nephrotoxicity and decreased Bone Mineral Density
  2. Tenofovir Alafenamide Fumarate (TAF)
    1. Tenofovir formulation released in 2016 and used in Genvoya, Descovy, Odefsey
    2. TAF appears to have less adverse Renal Function and Bone Mineral Density effects than the original TDF
    3. TAF is associated with greater weight gain and dyslipidemia than TDF

IV. Adverse Effects

  1. See nRTI for adverse effects attributed to the class
  2. Renal dysfunction
    1. Increased Serum Creatinine
    2. Proteinuria
    3. Electrolyte abnormalities
      1. Glycosuria
      2. Hypophosphatemia
    4. Acute Renal Failure (1% risk)
      1. Associated with longer duration of therapy, advanced HIV or pre-existing renal disease
  3. Gastrointestinal
    1. Diarrhea
    2. Nausea or Vomiting
    3. Flatulence
  4. Miscellaneous
    1. Headache
    2. Hepatitis B flares on withdrawal of medication

V. Dosing

  1. Dose: 300 mg orally daily

VI. Monitoring

  1. Obtain Urinalysis every 6 months when on Tenofovir Disoproxil Fumarate
  2. Obtain baseline Renal Function and Phosphorus, then at 2-8 weeks, and then every 3-6 months

Images: Related links to external sites (from Bing)

Related Studies

Cost: Medications

viread (on 3/22/2017 at Medicaid.Gov Survey of pharmacy drug pricing)
VIREAD 300 MG TABLET $34.28 each

Ontology: Tenefovir (C2735014)

Concepts Organic Chemical (T109) , Antibiotic (T195)
LNC MTHU034726
English Tenefovir